Good News for Daily CBD Consumers: Charlotte's Web Reports Second Cohort of CBD Safety Study Finds Zero Liver Toxicity and No Drowsiness

About this update from Charlotte's Web Holdings, Inc.

[{"type":"text","content":"\n \n \n \n Good News for Daily CBD Consumers: Charlotte's Web Reports Second Cohort of CBD Safety Study Finds Zero Liver Toxicity and No Drowsiness\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prngen3{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE; BORDER-TOP:1pt black; BORDER-RIGHT:1pt black; BORDER-BOTTOM:1pt black; BORDER-LEFT:1pt black\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Two human safety studies provide evidence that further addresses FDA's requests for liver safety data\n \n \n \n \n \n DENVER\n \n \n ,\n \n \n May 17, 2022\n \n \n /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) – Charlotte's Web Holdings, Inc. (\"Charlotte's Web\" or the \"Company\"), the science-driven CBD industry pioneer and global market leader, today shared the conclusions of the combined first and second cohort of the industry-sponsored liver safety study.  Cohort two added another 222 adults who daily consumed hemp CBD tinctures orally for 60 days. The second cohort combined with the first study cohort used 17 commercially available brands and 39 hemp CBD products across a total of 1,061 participants, increasing statistical certainty to 98%. The investigation's preliminary findings mirror the first cohort's results:  no association of increased prevalence of increased liver function test, no clinical liver disease, zero product related adverse events and new data concluding no daytime drowsiness and no testosterone deficiency.\n \n \n \n \n \n \n \n \n \n \"We were asked by Congressional leadership to understand and get answers to important safety questions posed by the FDA so they can confidently regulate these products.&#xA0...

More updates from Charlotte's Web Holdings, Inc.